Annalise Michaud
Psychiatric/Mental Health · Marion, INNPI 1245840081
Payments from drug & device makers
Across 653 payments — averaging $13.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$1K
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$1K
- Corium, LLC$805
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$762
- Neurocrine Biosciences, Inc.$603
- plus $3K from 22 others
What the payments were for
- Food & beverage$8,59098%
- Education$1562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 101 | $1,172 |
| Otsuka America Pharmaceutical, Inc. | 68 | $1,073 |
| AbbVie | 100 | $1,020 |
| Corium, LLC | 67 | $805 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 67 | $762 |
| Neurocrine Biosciences, Inc. | 48 | $603 |
| Vanda Pharmaceuticals Inc. | 39 | $555 |
| Axsome Therapeutics, Inc. | 19 | $356 |
| Supernus Pharmaceuticals, Inc. | 21 | $341 |
| Teva Pharmaceuticals USA, Inc. | 15 | $278 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $242 |
| Sunovion Pharmaceuticals Inc. | 21 | $230 |
| Alkermes, Inc. | 10 | $199 |
| Avanir Pharmaceuticals, Inc. | 12 | $176 |
| Noven Therapeutics, LLC | 8 | $138 |
| Johnson & Johnson | 7 | $115 |
| Tris Pharma Inc | 6 | $105 |
| Adlon Therapeutics L.p. | 5 | $98 |
| E.r. Squibb & Sons, L.L.C. | 3 | $89 |
| Idorsia Pharmaceuticals US Inc | 5 | $82 |
| Ironshore Pharmaceuticals Inc. | 4 | $70 |
| Merck | 4 | $61 |
| Collegium Pharmaceutical, Inc. | 3 | $55 |
| Acadia Pharmaceuticals Inc | 2 | $35 |
| Novo Nordisk | 2 | $35 |
| Eisai Inc. | 2 | $26 |
| Vertical Pharmaceuticals, LLC | 1 | $15 |
| Neos Therapeutics, LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$117
- Auvelity$116
How this compares
$8,746 in reported general payments places this provider in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 99 | $175,189 |
| RexultiBrexpiprazole | 61 | $126,603 |
| VraylarCariprazine Hcl | 59 | $82,722 |
| FanaptIloperidone | 35 | $69,498 |
| AuvelityDextromethorphan Hbr/Bupropion | 65 | $67,862 |
| BelsomraSuvorexant | 83 | $44,144 |
| TrintellixVortioxetine Hydrobromide | 54 | $40,157 |
| Abilify MaintenaAripiprazole | 14 | $38,402 |
| NuedextaDextromethorphan Hbr/Quinidine | 24 | $36,107 |
| Invega SustennaPaliperidone Palmitate | 11 | $29,382 |
| Oxtellar XrOxcarbazepine | 12 | $12,194 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $5,112 |
| Lamotrigine ErLamotrigine | 13 | $4,500 |
| Asenapine Maleate | 23 | $3,307 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 32 | $2,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $762 | $175,18999 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,073 | $165,00675 claims |
| AbbVieVraylar | $1,020 | $82,72259 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $555 | $69,49835 claims |
| Axsome Therapeutics, Inc.Auvelity | $356 | $67,86265 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $242 | $45,26867 claims |
| MerckBelsomra | $61 | $44,14483 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $176 | $36,10724 claims |
| Johnson & JohnsonInvega Sustenna | $115 | $29,38211 claims |
| Supernus Pharmaceuticals, Inc.Oxtellar Xr | $341 | $12,19412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 729 psychiatric/mental health providers in Indiana.
Other psychiatric/mental health in Marion
- Trina GreenwaldMarion$107K
- Brooke KempfTerre Haute$1.1M
- Gerald LewisMerrillville$336K
- Lauren LutzColumbus$320K
- Sonya RuedlingerIndianapolis$134K
- Paul DuncanJeffersonville$46K
- Morgan StamperConnersville$42K
- Jennifer JimenezUnion Mills$37K
- Savannah MullinsClarksville$31K
- Sharon ClevengerFort Wayne$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.